Photo of article from nejm.org
Apr 14, 2024, 22:26
Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial
Sergio Cifuentes Canaval, Cancer Research Project Manager at
“Exciting news from the ALINA trial! Alectinib, an oral tyrosine kinase inhibitor, has shown remarkable results in resected ALK-positive NSCLC. Patients receiving alectinib had a 76% lower risk of disease recurrence or death compared to chemotherapy. Promising outcomes with a low-grade safety profile.
Wu Y-L et al. have just released the results of a groundbreaking preplanned interim analysis from the **ALINA trial**.
- Phase III, patients with resected ALK NSCLC
- 257 patients stages IB, II, or IIIA
- Randomly 1:1 to Alectinib 2 years vs Platinum-Based Chemotherapy for four cycles
- Primary Endpoint: DFS
- Median follow-up of 27.8 months, alectinib with a 76% lower risk of disease recurrence or death compared to chemotherapy
Implications:
- Alectinib represents a paradigm shift in the battle against early-stage, resectable ALK-positive lung cancer.
- It not only improves patient outcomes but also reduces the risk of disease recurrence.”